15.37  -0.36 (-2.29%)		06-18 16:00
Open: 16.096 High: 16.16 Volume: 19,553,824		Pre. Close: 15.73 Low: 14.94 Market Cap: 17,899(M)

Short term
Mid term
Targets	6-month :	19.22	1-year :	20.32
Resists	First :	16.46	Second :	17.4
Pivot price	15.94
Supports	First :	14.93	Second :	12.43
MAs	MA(5) :	15.98	MA(20) :	16.04
	MA(100) :	14.85	MA(250) :	12.06
MACD	MACD :	0	Signal :	0.1
%K %D	K(14,3) :	31.2	D(3) :	46.3
RSI	RSI(14): 42
52-week	High :	17.4	Low :	8.3

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ VTRS ] has closed above bottom band by 2.2%. Bollinger Bands are 42.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	16.18 - 16.3	16.3 - 16.38
Low:	14.66 - 14.8	14.8 - 14.92
Close:	15.17 - 15.37	15.37 - 15.52

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

Thu, 18 Jun 2026
Viatris Completes €650 Million 4.250% Senior Notes Due 2033 to Refinance 2026 Debt - TradingView

Thu, 18 Jun 2026
Viatris (NASDAQ: VTRS) issues €650M 4.25% notes to help refinance 2026 debt - Stock Titan

Mon, 15 Jun 2026
Viatris launches €650M 4.250% senior notes due 2033 offering - TradingView

Mon, 15 Jun 2026
Viatris (VTRS) prices €650M 4.250% senior notes maturing 2033 - Stock Titan

Mon, 15 Jun 2026
Viatris (VTRS) sells €650M 4.25% senior notes to refinance 2026 debt - Stock Titan

Mon, 15 Jun 2026
Viatris Inc. (VTRS) Stock Analysis: Navigating Growth Prospects with an 8.09% Potential Upside - DirectorsTalk Interviews

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	1,160 (M)
Shares Float	1,160 (M)
Held by Insiders	0.4 (%)
Held by Institutions	87.2 (%)
Shares Short	41,120 (K)
Shares Short P.Month	37,780 (K)

EPS	-0.31
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	12.77
Profit Margin	-2.1 %
Operating Margin	6.7 %
Return on Assets (ttm)	2.3 %
Return on Equity (ttm)	-2 %
Qtrly Rev. Growth	8.1 %
Gross Profit (p.s.)	5
Sales Per Share	12.55
EBITDA (p.s.)	3.56
Qtrly Earnings Growth	0 %
Operating Cash Flow	2,170 (M)
Levered Free Cash Flow	2,240 (M)

PE Ratio	-51.24
PEG Ratio	0.1
Price to Book value	1.2
Price to Sales	1.22
Price to Cash Flow	8.21

Dividend	0.11
Forward Dividend	0
Dividend Yield	0.7%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.